New hope for bile duct cancer: drug combo shows promise in late-stage trial
NCT ID NCT05771480
First seen Nov 21, 2025 · Last updated May 05, 2026 · Updated 20 times
Summary
This study tests a drug called durvalumab combined with standard chemotherapy for people with advanced biliary tract cancer (bile duct or gallbladder cancer) that cannot be removed by surgery. The goal is to see if the combination is safe and helps patients live longer or shrink their tumors. About 142 adults with this rare cancer are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Mobile, Alabama, 36607, United States
-
Research Site
Orange, California, 92868, United States
-
Research Site
Washington D.C., District of Columbia, 20007, United States
-
Research Site
Portland, Oregon, 97213, United States
-
Research Site
Clichy, 92110, France
-
Research Site
Dijon, 21079, France
-
Research Site
Montpellier, 34090, France
-
Research Site
Villejuif, 94800, France
-
Research Site
Chemnitz, 09131, Germany
-
Research Site
Hanover, 30625, Germany
-
Research Site
Castelfranco Veneto, 31033, Italy
-
Research Site
Foggia, 71122, Italy
-
Research Site
Palermo, 90146, Italy
-
Research Site
Pisa, 56126, Italy
-
Research Site
Rozzano, 20089, Italy
-
Research Site
Chūōku, 104-0045, Japan
-
Research Site
Kanazawa, 920-8641, Japan
-
Research Site
Kashiwa, 227-8577, Japan
-
Research Site
Kyoto, 606-8507, Japan
-
Research Site
Osaka, 541-8567, Japan
-
Research Site
Sendai, 980-8574, Japan
-
Research Site
Ube, 755-8505, Japan
-
Research Site
Wakayama, 641-8509, Japan
-
Research Site
Yokohama, 241-8515, Japan
-
Research Site
Singapore, 169610, Singapore
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Seoul, 06351, South Korea
-
Research Site
Barcelona, 08035, Spain
-
Research Site
Madrid, 28027, Spain
-
Research Site
Madrid, 28040, Spain
-
Research Site
Madrid, 28041, Spain
-
Research Site
Pamplona, 31008, Spain
-
Research Site
Seville, 41013, Spain
Conditions
Explore the condition pages connected to this study.